Sumatriptan

Spezifikationen

103628-46-2CAS-Nummer

600-462-9EG-Nummer

1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamideIUPAC-Name

C14H21N3O2SChemische Formel

295.4 g/molMolekulargewicht

sumatriptan; 103628-46-2; Imitrex; Sumatran; Sumax; Imigran; Sumatriptanum; 1-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; DTXSID4023628; Imigran Recovery; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; TOSYMRA; 8R78F6L9VO; DFN-11; 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide; N02CC01; 1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; DFN-11 (SUMATRIPTAN INJECTION); DTXCID303628; CHEBI:10650; (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide; 1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl-; 3-(2-(Dimethylamino)ethyl)-N-methylindole-5-methanesulfonamide; Imigran Radis; (3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide; {3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; 1-(3-(2-dimethylaminoethyl)-1H-indol-5-yl)-N-methyl-methanesulfonamide; 1-(3-(2-dimethylaminoethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide; GR43175; Succinate, Sumatriptan; RefChem:56076; 600-462-9; GR 43175; Imitrex (TN); CHEMBL128; MFCD00866222; NCGC00095838-01; Sumatriptanum [INN-Latin]; GR-43175; GR 43175X; SMR000596517; Imigran (TN); CAS-103628-46-2; BRN 6930870; UNII-8R78F6L9VO; Sumatriptan (JAN/USP/INN); Sumatriptan [USP:INN:BAN]; AVP825; HSDB 7742; AVP 825; AVP-825; Tosymra (nasal spray); Sumatriptan Impurity 16; SUMATRIPTAN [MI]; SUMATRIPTAN [INN]; SUMATRIPTAN [JAN]; SUMATRIPTAN [HSDB]; GTPL54; SUMATRIPTAN [VANDF]; SCHEMBL1482; SUMATRIPTAN [MART.]; BSPBio_002304; SUMATRIPTAN [USP-RS]; SUMATRIPTAN [WHO-DD]; MLS001195659; MLS001304742; BIDD:GT0248; SPECTRUM1505372; orb1704027; SCHEMBL29450235; Sumatriptan - Bio-X trade mark; HY-B0121B; SUMATRIPTAN [ORANGE BOOK]; HMS2231B21; HMS3369A05; SUMATRIPTAN [USP MONOGRAPH]; ALBB-038603; MSK11291; Tox21_111528; BDBM50005835; EBC-26501; 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methyl-methanesulfonamide; AKOS015894924; Tox21_111528_1; CCG-230331; DB00669; NCGC00095838-02; NCGC00095838-03; NCGC00095838-04; NCGC00095838-06; BS164424; FD146133; SY398829; SBI-0206837.P001; CS-0009565; NS00009397; C07319; C90357; D00451; EN300-123008; T23405; AB00698285-12; AB00698285-13; AB00698285_14; AB00698285_15; F600616; L000584; Q416978; BRD-K50938287-001-01-7; BRD-K50938287-001-09-0; BRD-K50938287-036-12-0; BRD-K50938287-036-13-8; 3-[2-(Dimethylamino)ethyl]-N-methy-1H-indole-5-methanesulfonamide; 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide; (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide #; 1-[3-[2-(Dimethylamino)ethyl]-5-indolyl]-N-methylmethanesulfonamide; 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole -5-methanesulphonamideSynonyme